T B Brunner

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi Progress towards the use of HIV protease inhibitors in cancer therapy
    Eric J Bernhard
    Oxford University, Radiation Oncology and Biology, Radiobiology Research Institute, Headington, Oxford, United Kingdom
    Cancer Biol Ther 7:636-7. 2008
  2. pmc Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Wor
    Thomas B Brunner
    Department of Radiation Oncology of the University at Erlangen Nuremberg, Erlangen, Germany
    BMC Cancer 7:41. 2007
  3. pmc Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients
    Thomas B Brunner
    Radiation Oncology of the Friedrich Alexander University of Erlangen Nuremberg, Universitätsstraße 22, 91054 Erlangen, Germany
    Radiat Oncol 6:88. 2011
  4. doi Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma
    Thomas B Brunner
    Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom
    Strahlenther Onkol 186:672-80. 2010
  5. pmc The role of radiotherapy in multimodal treatment of pancreatic carcinoma
    Thomas B Brunner
    Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, UK
    Radiat Oncol 5:64. 2010
  6. doi Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
    Thomas B Brunner
    Gray Institute of Radiation Oncology and Biology, University of Oxford, Churchill Hospital, Oxford, United Kingdom
    J Clin Oncol 26:2699-706. 2008
  7. doi Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost
    Thomas B Brunner
    Department of Radiation Therapy, Friedrich Alexander University of Erlangen Nuremberg, Erlangen
    Strahlenther Onkol 184:15-22. 2008
  8. ncbi [The role of radiochemotherapy in multimodal therapy of pancreatic cancer]
    T B Brunner
    Strahlenklinik des Universitätsklinikums Erlangen der Friedrich Alexander Universität Erlangen Nürnberg
    Dtsch Med Wochenschr 132:808-12. 2007
  9. ncbi Adjuvant and neoadjuvant radiochemotherapy in ductal pancreatic carcinoma
    T B Brunner
    Department of Radiation Therapy, Friedrich Alexander University Erlangen Nurnberg, Germany
    Strahlenther Onkol 176:265-73. 2000
  10. ncbi Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients
    Thomas B Brunner
    Department of Radiation Oncology, Friedrich Alexander University of Erlangen Nuremberg, Universitätstrasse 27, 91054 Erlangen, Germany
    Strahlenther Onkol 182:210-5. 2006

Detail Information

Publications25

  1. ncbi Progress towards the use of HIV protease inhibitors in cancer therapy
    Eric J Bernhard
    Oxford University, Radiation Oncology and Biology, Radiobiology Research Institute, Headington, Oxford, United Kingdom
    Cancer Biol Ther 7:636-7. 2008
    ..It is this point that Plasteras et al. address in the current issue of Cancer Biology & Therapy, by examining the effects of combined treatment with radiation and HIV protease inhibitors.(3)...
  2. pmc Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Wor
    Thomas B Brunner
    Department of Radiation Oncology of the University at Erlangen Nuremberg, Erlangen, Germany
    BMC Cancer 7:41. 2007
    ..Furthermore, the synopsis of the overall survival results of neoadjuvant trials suggests a higher rate compared to adjuvant trials...
  3. pmc Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients
    Thomas B Brunner
    Radiation Oncology of the Friedrich Alexander University of Erlangen Nuremberg, Universitätsstraße 22, 91054 Erlangen, Germany
    Radiat Oncol 6:88. 2011
    ..The aim of this retrospective analysis was to evaluate the effect of two concurrent chemoradiotherapy regimens using 5-fluorouracil or gemcitabine to compare their effect and tolerance...
  4. doi Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma
    Thomas B Brunner
    Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom
    Strahlenther Onkol 186:672-80. 2010
    ..this report aims to provide an overview on radiotherapy and chemotherapy in extrahepatic biliary duct carcinoma (BDC)...
  5. pmc The role of radiotherapy in multimodal treatment of pancreatic carcinoma
    Thomas B Brunner
    Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, UK
    Radiat Oncol 5:64. 2010
    ..Whenever possible, radiotherapy should be performed as simultaneous chemoradiotherapy. Patients with PDAC should be offered entry into clinical trials to identify optimal treatment results...
  6. doi Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
    Thomas B Brunner
    Gray Institute of Radiation Oncology and Biology, University of Oxford, Churchill Hospital, Oxford, United Kingdom
    J Clin Oncol 26:2699-706. 2008
    ..Preclinically, HIV protease inhibitors radiosensitize tumors with activated PI3-kinase/Akt pathway. We determined the toxicity of nelfinavir chemoradiotherapy in borderline resectable and unresectable pancreatic cancer...
  7. doi Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost
    Thomas B Brunner
    Department of Radiation Therapy, Friedrich Alexander University of Erlangen Nuremberg, Erlangen
    Strahlenther Onkol 184:15-22. 2008
    ..To present the results of a prospective phase II study in esophageal carcinoma...
  8. ncbi [The role of radiochemotherapy in multimodal therapy of pancreatic cancer]
    T B Brunner
    Strahlenklinik des Universitätsklinikums Erlangen der Friedrich Alexander Universität Erlangen Nürnberg
    Dtsch Med Wochenschr 132:808-12. 2007
  9. ncbi Adjuvant and neoadjuvant radiochemotherapy in ductal pancreatic carcinoma
    T B Brunner
    Department of Radiation Therapy, Friedrich Alexander University Erlangen Nurnberg, Germany
    Strahlenther Onkol 176:265-73. 2000
    ..Ductal pancreatic carcinoma ranks third among malignancies of the gastrointestinal tract and its incidence is rising. Today, patients with this disease still have fatal prognosis necessitating efforts towards more effective treatment...
  10. ncbi Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients
    Thomas B Brunner
    Department of Radiation Oncology, Friedrich Alexander University of Erlangen Nuremberg, Universitätstrasse 27, 91054 Erlangen, Germany
    Strahlenther Onkol 182:210-5. 2006
    ..The aim of the present study was to retrospectively assess overall survival and toxicity of chemotherapy in addition to chemoradiation in this patient group...
  11. ncbi Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma. A retrospective analysis
    Thomas B Brunner
    Department of Radiation Oncology, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany
    Strahlenther Onkol 180:751-7. 2004
    ..This study compared stenting and chemoradiation (CRT) and attempted to identify factors that are predictive of response to CRT...
  12. ncbi Large topographic variability of upper abdominal lymphatics and the consequences for radiation treatment planning
    Thomas B Brunner
    Department of Radiation Oncology, University Hospitals of Erlangen, Erlangen, Germany
    Radiother Oncol 81:190-5. 2006
    ..Lymphatics follow the large vessels of this region. Vascular variability with consequences for planning treatment volume (PTV) was studied...
  13. doi Radiotherapy in pancreatic cancer
    Gunther Klautke
    Department of Radiation Therapy, University of Rostock, Rostock, Germany
    Strahlenther Onkol 184:557-64. 2008
    ..The results of meta-analyses, phase III-studies, and phase II-studies using chemoradiation (CRT) and chemotherapy for resectable and non-resectable PDAC are reviewed...
  14. ncbi Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis
    Thomas B Brunner
    Department of Radiation Oncology, Friedrich Alexander University of Erlangen Nuremberg, Universitätstrasse 27, 91054 Erlangen Nuremberg, Germany
    Int J Radiat Oncol Biol Phys 62:1021-9. 2005
    ..We aimed to define guidelines for elective treatment of nodal areas based on pathologic nodal involvement to optimize treatment volume for this tumor...
  15. doi Adenocarcinoma of the esophagogastric junction: the pattern of metastatic lymph node dissemination as a rationale for elective lymphatic target volume definition
    Iris Meier
    Department of Radiation Oncology, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany
    Int J Radiat Oncol Biol Phys 70:1408-17. 2008
    ..We aimed to clarify the lymph node (LN) distribution of AEG according to location of the tumor mass and invasion of neighboring areas for the selection of radiotherapy planning target volume (PTV) margins...
  16. doi Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation
    Dominik Tinkl
    Department of Radiation Oncology, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany
    Strahlenther Onkol 185:557-66. 2009
    ..This approach was tested in a cohort to estimate its effect on survival...
  17. doi Comparison of four target volume definitions for pancreatic cancer. Guidelines for treatment of the lymphatics and the primary tumor
    E Fokas
    Gray Institute for Radiation Oncology and Biology, Department of Oncology, Oxford Cancer Centre, University of Oxford
    Strahlenther Onkol 189:407-16. 2013
    ..We aimed to measure the percentages of anatomical coverage of eLNs by comparing four different contouring guidelines...
  18. ncbi Radiation sensitization by inhibition of activated Ras
    Thomas B Brunner
    Department of Radiation Oncology, University Hospital, Erlangen, Germany
    Strahlenther Onkol 180:731-40. 2004
    ..This article reviews preclinical and phase I clinical studies that reported on combining inhibition of activated Ras and downstream effectors of Ras with radiotherapy...
  19. ncbi Predictive and prognostic factors in small cell lung carcinoma (SCLC)--analysis from routine clinical practice
    Wolfgang M Brueckl
    Department of Medicine 1, University Hospital Erlangen, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany
    Anticancer Res 26:4825-32. 2006
    ..Prognostic and predictive factors of routine clinical practice among patients with small cell lung carcinoma (SCLC) were evaluated...
  20. ncbi Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer
    Thomas B Brunner
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Int J Radiat Oncol Biol Phys 55:144-53. 2003
    ..We used a time-dependent schedule to determine the maximal-tolerated dose and dose-limiting toxicities (DLTs; Grade 4 hematologic or Grade 3 other toxicity)...
  21. pmc Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells
    Keith A Cengel
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
    Neoplasia 9:341-8. 2007
    ..Taken together, these findings suggest that EGFR-activated H-Ras signaling is initiated by oncogenic K-Ras to promote radiation survival in pancreatic and colorectal cancers...
  22. ncbi Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras
    Thomas B Brunner
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6072, USA
    Cancer Res 65:8433-41. 2005
    ..Farnesyltransferase inhibitors could therefore be of use as sensitizers for pancreatic carcinoma radiotherapy...
  23. ncbi A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer
    Neil E Martin
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 10:5447-54. 2004
    ....
  24. ncbi Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations
    Thomas B Brunner
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia 19104 6072, USA
    Cancer Res 63:5656-68. 2003
    ..We conclude that the rational combination of FTIs with other therapies, taking into account the biological activities of the individual agents, may improve the clinical results obtained with FTIs...
  25. ncbi Molecular verification of stereotactic radiotherapy in rats using ATMpS1981 immunofluorescence
    Thomas B Brunner
    Department of Radiation Oncology, University Hospitals of Erlangen, Germany
    Radiother Oncol 79:109-14. 2006
    ..Spatial accuracy of dose-delivery is crucial and needs to be proven. This study intended to show on a molecular level precision of STS using the radiation activated molecule phospho-serine 1981-ATM (ATMpS1981)...